Eli Lilly stock slips as new Phase 3 obesity drug data released, Eli Lilly and Company reports

Traders Union
All News
Business & Wealth
Companies
Eli Lilly slips 0.46% today

Highlights

LLY maintains a strong bullish trend across all timeframes, trading well above major moving average supports.
Momentum remains positive with buy signals from trend indicators, though oscillators flag overbought conditions and possible short-term pullbacks.
LLY is expected to consolidate between $1,075 and $1,165 this week, with a breakout above resistance possibly leading to new highs.

Patients on the 12 mg dose lost an average of 70 pounds, or 28.3%, over 80 weeks. The company released the new data today.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish momentum sustained as price holds above key technical supports

LLY is trading at $1,120.05, which is firmly above the MA-20 ($1,045.74), MA-50 ($972.74), and MA-200 ($947.52), confirming strong bullish trends in the short, medium, and long term. The Ichimoku Kijun at $1,031.42 sits below the current price and acts as immediate support, with near-term support at MA-20 and key support at MA-50, while near-term resistance is found at the recent high of $1,166 and further at the 52-week high.

Overbought oscillators flag caution despite persistent intraday buying strength

Momentum readings remain positive, with MACD and ADX both indicating a “Buy” on D1, suggesting bullish sentiment. However, oscillators show signs of caution: RSI is elevated at 66, CCI and BBP are overbought, and Stoch RSI signals a neutral position, highlighting some divergence and the potential for short-term pullbacks. BBP’s high value confirms buyers are still in control intraday, though oscillators warn of stretched conditions. LLY has gained $16.59 (1.50%) over the past week from a previous close at $1,103.46, with the price now in the middle of this week’s range and weekly volatility standing at 10.82%. The tone for the week is one of consolidation after testing both extremes of the recent range.

Upside favored as volatility guides tight range near annual peaks

For the coming week, the expected price range is $1,075 to $1,165, anchored around the current price and respecting recent weekly volatility, which keeps LLY near its 52-week high and well above the yearly low. With all major W1 indicators (RSI, ADX, MACD, MA-50) showing “Buy,” there is a very high probability (more than 80%) of further gains, while the chance of a pullback is very low. The baseline scenario sees LLY consolidating between $1,075 and $1,165. If bullish momentum prevails, a break above resistance near $1,165 could open the way to new highs. Conversely, a bearish turn breaking $1,075 could trigger a test of lower supports, though such a move appears less likely given the prevailing trend strength.

Previously it was reported that Eli Lilly maintained a constructive bullish outlook, with technical analysis suggesting ongoing price strength amidst sideways consolidation. The current article builds on this perspective, underscoring that monitoring for a confirmed breakout or breakdown remains critical for traders as the near-term scenario continues to evolve.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.